Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer

Figure 2

Kaplan-Meier estimates for (a) progression-free survival and (b) overall survival. P values were based on one-sided log-rank test stratified by Eastern Cooperative Oncology Group performance status and gender. Progression-free survival was based on data cutoff date of December 21, 2011 and overall survival was based on the most recent data at the time of final database lock on May 18, 2012. CI, confidence interval; Cont, continuously; HR, hazard ratio; mod, modified schedule; mOS, median overall survival; mPFS, median progression-free survival.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us